Differential effects of GPA 1851 on hepatic microsomal drug metabolism dependent on dosage and time of sacrifice

Effect of metyrapone on tryptophan binding to rat hepatic nuclei

This study evaluated whether metyrapone (2-methyl-1,2-di-3-pyridyl-1-propanone), an inhibitor of endogenous adrenal corticosteroid synthesis via inhibition of cytochrome P-450-mediated steroid hydroxylation, would influence the binding of L-tryptophan to rat hepatic nuclei or nuclear envelopes. Previous publications have indicated that binding of L-tryptophan to hepatic nuclear envelope proteins was saturable, stereospecific, and of high affinity. In this study, we investigated whether metyrapone would influence L-tryptophan binding to rat hepatic nuclei or nuclear envelopes as assayed by in vitro L-(5-3H)tryptophan binding. Our results indicate that the addition of metyrapone in vitro has little influence on L-(5-3H)tryptophan binding to hepatic nuclei or nuclear envelopes. On the other hand, when metyrapone (1 mg/100 g body weight) is tube-fed 30 minutes before killing, the isolated hepatic nuclei show decreased specific L-tryptophan binding (total binding minus nonspecific binding [using 2,000-fold excess of unlabeled L-tryptophan]) compared with controls. Also, addition of metyrapone in vitro to rat liver before homogenization and preparation of nuclei caused the nuclei to show decreased specific tryptophan binding compared with controls. Under these in vitro conditions, SKF 525A, another inhibitor of hydroxylation, showed inhibitory effects similar to those of metyrapone. Thus, metyrapone can interfere with rat liver nuclear envelope receptor binding to L-tryptophan, and possibly acts via its effects on hydroxylation. At high doses, metyrapone (20 mg/100 g body weight) appears to inhibit tryptophan-induced stimulation of hepatic protein synthesis.

Comparison of in vivo and in vitro methods for assessing the effects of carbon tetrachloride on the hepatic drug-metabolizing enzyme system

The effect of a single i.p. injection of 0, 20, 200, and 1000 microliter/kg carbon tetrachloride on the activity of the hepatic drug-metabolizing enzyme system was measured in the rat by a model substrate assay employing lindane (gamma-hexachlorocyclohexane) and by a battery of in vitro enzyme assays. The data in this study indicated that carbon tetrachloride had a biphasic influence on the phase I reactions with the lowest dose inducing a significant increase in enzyme activity while the highest dose produced significant inhibition. Significant CCl4-induced reductions in glucuronyltransferase and sulfotransferase activities were also observed while the effect on glutathione-S-transferase was ambiguous. The in vivo and in vitro assays showed good agreement.

Induction of hepatic cytochrome P-450 and drug metabolism by metyrapone in the rat: relevance to its effects in rat-liver cell culture

The ability of metyrapone to induce hepatic cytochrome P-450 and xenobiotic metabolism in rats and rat hepatocyte culture has been studied. Metyrapone is a phenobarbitone-type inducer in rats. When rat hepatocytes were cultured with beta-naphthoflavone, a polycyclic hydrocarbon-type induction pattern was observed. In contrast, the observed induction pattern of both phenobarbitone and metyrapone in cell culture differed from that obtained with these compounds in vivo. The relationship between the nature of the induction of hepatic xenobiotic metabolism by metyrapone in vivo and its effects in liver-cell culture are discussed.

Induction of microsomal drug-metabolizing enzymes caused by hexobarbital

Hexobarbital was given to anaesthetized mice for a period of 7 h by repeated i. p. injection, first of 100 mg/kg,then several times of 50 mg/kg. A high level of hexobarbital was maintained in the liver. The activity of microsomal drug-metabolizing enzymes was induced by this treatment with hexobarbital. 30 min after a single i. p. injection of 100 mg/kg of hexobarbital, there was a significant inhibition of aminopyrine N-demethylase but none of cytochrome c and neotetrazolium reductases. Hexobarbital in vitro inhibits aminopyrine N-demethylase but not cytochrome c reductase.